CONTEXT: The prevalence of scoliosis in children with Prader-Willi syndrome (PWS) is 30-80%, depending on age. Although reports about effects of GH treatment on scoliosis in children with PWS are limited, scoliosis is generally considered a contraindication for GH treatment. OBJECTIVE: The aim was to study the effects of GH treatment on the onset of scoliosis and curve progression in children with PWS. DESIGN: We conducted a multicenter, randomized, controlled GH study in infants and prepubertal and pubertal children. Infants and prepubertal children were randomized into a GH-treated group (1.0 mg/m(2) . d) and a control group for 1 and 2 yr, respectively. Pubertal children were randomized to receive somatropin 1.0 or 1.5 mg/m(2) . d. Yearly, x-rays of the spine were taken, and height, weight, truncal lean body mass (with dual energy x-ray absorptiometry), and IGF-I were measured. PATIENTS: A total of 91 children with PWS (median age, 4.7 yr; interquartile range, 2.1-7.4) participated in the study. MAIN OUTCOME MEASURES: We measured the onset of scoliosis (Cobb >10 degrees ) and scoliotic curve progression. RESULTS:GH-treated children had similar onset of scoliosis and curve progression as randomized controls (P = 0.27-0.79 and P = 0.18-0.98, respectively). GH treatment, IGF-I sd score (SDS), and catch-up growth had no adverse effect on the onset of scoliosis or curve progression, even after adjustment for confounders. Height SDS, truncal lean body mass, and IGF-I SDS were significantly higher in GH-treated children than in randomized controls. At baseline, a higher IGF-I SDS was associated with a lower severity of scoliosis. CONCLUSIONS: Scoliosis should no longer be considered a contraindication for GH treatment in children with PWS.
RCT Entities:
CONTEXT: The prevalence of scoliosis in children with Prader-Willi syndrome (PWS) is 30-80%, depending on age. Although reports about effects of GH treatment on scoliosis in children with PWS are limited, scoliosis is generally considered a contraindication for GH treatment. OBJECTIVE: The aim was to study the effects of GH treatment on the onset of scoliosis and curve progression in children with PWS. DESIGN: We conducted a multicenter, randomized, controlled GH study in infants and prepubertal and pubertal children. Infants and prepubertal children were randomized into a GH-treated group (1.0 mg/m(2) . d) and a control group for 1 and 2 yr, respectively. Pubertal children were randomized to receive somatropin 1.0 or 1.5 mg/m(2) . d. Yearly, x-rays of the spine were taken, and height, weight, truncal lean body mass (with dual energy x-ray absorptiometry), and IGF-I were measured. PATIENTS: A total of 91 children with PWS (median age, 4.7 yr; interquartile range, 2.1-7.4) participated in the study. MAIN OUTCOME MEASURES: We measured the onset of scoliosis (Cobb >10 degrees ) and scoliotic curve progression. RESULTS: GH-treated children had similar onset of scoliosis and curve progression as randomized controls (P = 0.27-0.79 and P = 0.18-0.98, respectively). GH treatment, IGF-I sd score (SDS), and catch-up growth had no adverse effect on the onset of scoliosis or curve progression, even after adjustment for confounders. Height SDS, truncal lean body mass, and IGF-ISDS were significantly higher in GH-treated children than in randomized controls. At baseline, a higher IGF-ISDS was associated with a lower severity of scoliosis. CONCLUSIONS:Scoliosis should no longer be considered a contraindication for GH treatment in children with PWS.
Authors: Jennifer Proffitt; Kathryn Osann; Barbara McManus; Virginia E Kimonis; Janalee Heinemann; Merlin G Butler; David A Stevenson; June-Anne Gold Journal: Am J Med Genet A Date: 2018-12-19 Impact factor: 2.802
Authors: Emma L Wakeling; Frédéric Brioude; Oluwakemi Lokulo-Sodipe; Susan M O'Connell; Jennifer Salem; Jet Bliek; Ana P M Canton; Krystyna H Chrzanowska; Justin H Davies; Renuka P Dias; Béatrice Dubern; Miriam Elbracht; Eloise Giabicani; Adda Grimberg; Karen Grønskov; Anita C S Hokken-Koelega; Alexander A Jorge; Masayo Kagami; Agnes Linglart; Mohamad Maghnie; Klaus Mohnike; David Monk; Gudrun E Moore; Philip G Murray; Tsutomu Ogata; Isabelle Oliver Petit; Silvia Russo; Edith Said; Meropi Toumba; Zeynep Tümer; Gerhard Binder; Thomas Eggermann; Madeleine D Harbison; I Karen Temple; Deborah J G Mackay; Irène Netchine Journal: Nat Rev Endocrinol Date: 2016-09-02 Impact factor: 43.330
Authors: Lynda E Polgreen; William Thomas; Paul J Orchard; Chester B Whitley; Bradley S Miller Journal: Mol Genet Metab Date: 2013-12-11 Impact factor: 4.797
Authors: Aaron L Carrel; Susan E Myers; Barbara Y Whitman; Jens Eickhoff; David B Allen Journal: J Clin Endocrinol Metab Date: 2010-01-08 Impact factor: 5.958
Authors: Juan A Rodriguez; Emily C Bruggeman; Bharath K Mani; Sherri Osborne-Lawrence; Caleb C Lord; Henry F Roseman; Hannah L Viroslav; Prasanna Vijayaraghavan; Nathan P Metzger; Deepali Gupta; Kripa Shankar; Claudio Pietra; Chen Liu; Jeffrey M Zigman Journal: Endocrinology Date: 2018-12-01 Impact factor: 4.736